Related Experiment Video
Updated: Dec 20, 2025
11:38
Voluntary Breath-hold Technique for Reducing Heart Dose in Left Breast Radiotherapy
Published on: July 3, 2014
47.3K
Beta-Blockers and Cancer: Where Are We?
Rita Peixoto1, Maria de Lourdes Pereira2, Miguel Oliveira1,3
1Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal.
Pharmaceuticals (Basel, Switzerland)
|May 30, 2020
Summary
Beta-blockers, like propranolol, show promise as complementary cancer treatments. They may improve cancer outcomes by reducing tumor growth and spread, offering a way to enhance treatment effectiveness while minimizing harm to healthy cells.
Area of Science:
- Oncology
- Pharmacology
Background:
- Cancer is a leading global cause of mortality, with current treatments like chemotherapy and radiotherapy often causing significant toxicity to normal cells.
- There is a critical need for more effective cancer therapies that enhance treatment success rates while reducing side effects.
Purpose of the Study:
- To review existing literature on the role of beta-blockers (BBs) in cancer treatment.
- To evaluate the potential of BBs as an adjunct therapy for various cancer types.
Main Methods:
- Literature review of studies investigating cancer treatments and beta-blockers.
- Analysis of beta-blocker mechanisms, including adrenergic receptor antagonism.
Main Results:
- Beta-blockers inhibit mechanisms involved in tumorigenesis, angiogenesis, and metastasis.
- Propranolol demonstrated potential in improving cancer outcomes by reducing cancer cell proliferation rates in reviewed studies.
Conclusions:
- Beta-blockers, particularly propranolol, may serve as a complementary treatment to improve cancer outcomes.
- Further in vitro research is necessary to fully elucidate the protective mechanisms of beta-blockers in cancer patients.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.4K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.4K
01:28Antihypertensive Drugs: Types of β-Blockers
1.3K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.3K
01:22Heart Failure Drugs: β-Blockers
671
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
671
01:17Antihypertensive Drugs: Action of β1 Blockers
1.8K
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
1.8K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.2K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.2K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K